$1.55 trillion in regulated AI. Zero competitors in governed AI.
At a healthcare AI conference last year, a vendor took the stage and said something remarkable: “Our model achieves 97.3% accuracy on retrospective mammography data.”
The audience applauded. The slides were beautiful. The demo was slick. Nobody asked the obvious question.
A radiologist in the fourth row raised her hand. “Can you show me the evidence chain for a specific recommendation? If my patient follows your AI’s advice and something goes wrong, what do I show the malpractice attorney?”
The vendor smiled. “We can discuss our validation methodology offline.”
That radiologist is CANONIC’s customer. And there are millions of her.
The Empty Quadrant
Map the AI healthcare market on two axes. The vertical axis is specialization — how deeply does the vendor understand the clinical domain? The horizontal axis is evidence — how well can they prove their output is correct?
Most vendors cluster in one quadrant: high specialization, low evidence. They know mammography. They know oncology. They’ve published papers. But ask for a cryptographic evidence chain linking a specific recommendation to a specific clinical guideline to a specific clinician’s validation — and you get silence. Or a slide deck.
A few vendors occupy the opposite quadrant: low specialization, high evidence. They build generic AI audit tools. They can tell you what happened, but they don’t know a BI-RADS 4 from a blood pressure cuff.
The quadrant that’s empty — high specialization + high evidence — is where clinical AI actually needs to live. Deep domain knowledge backed by mathematical proof. That’s where CANONIC sits. Alone.
The Trillion-Dollar Gap
| Sector | TAM | What They Need |
|---|---|---|
| Healthcare | $500B+ | Evidence chains that survive litigation |
| Finance | $400B+ | Audit trails that satisfy regulators |
| AI/ML | $300B+ | EU AI Act compliance by 2026 |
| Defense | $200B+ | FedRAMP, CMMC, zero-trust |
| Technology | $150B+ | SOC2, ISO 27001, GDPR |
Total addressable market: $1.55 trillion. And the governance quadrant is empty across every sector.
The EU AI Act enters full force in 2026. It requires risk assessments, transparency obligations, and conformity assessments for high-risk AI. Healthcare AI is high-risk. Financial AI is high-risk. The compliance deadline isn’t theoretical. It’s on the calendar. And organizations deploying AI have two choices: bolt governance on after the fact, or build on a framework that was governed from the start.
Why Nobody Else Is Here
Building governed AI is harder than building accurate AI. Accuracy is a model problem — more data, better hyperparameters, higher F1 scores. Governance is a systems problem — evidence chains, audit trails, credential validation, cryptographic provenance, mathematical compliance scoring.
Most AI companies are founded by ML researchers who solve model problems. The governance gap isn’t a market failure. It’s a capability gap. Building the framework requires a different kind of expertise: the kind that comes from an MSE in Systems Engineering at Penn, a PhD in Genomics, an MD, 23 years in academic medicine, 65 peer-reviewed publications, four clinical trials, $38M+ in funded research — and the experience of watching an AI hallucinate in a clinical setting and knowing nobody could trace why.
The quadrant isn’t empty because nobody wants to be there. It’s empty because nobody else has built the tools to get there.
Figures
| Context | Type | Data |
|---|---|---|
| post | balance | left: Low Evidence, right: High Evidence, tilt: -15 |
CANONIC — The quadrant nobody else occupies.